CDH17 [3H2] Monoclonal Antibody
- Known as:
- CDH17 [3H2] Monoclonal Antibody
- Catalog number:
- 51-900
- Product Quantity:
- 0.05 mg
- Category:
- -
- Supplier:
- Prosci
- Gene target:
- CDH17 [3H2] Monoclonal Antibody
Related genes to: CDH17 [3H2] Monoclonal Antibody
- Gene:
- CDH17 NIH gene
- Name:
- cadherin 17
- Previous symbol:
- -
- Synonyms:
- HPT-1, cadherin
- Chromosome:
- 8q22.1
- Locus Type:
- gene with protein product
- Date approved:
- 1997-02-10
- Date modifiied:
- 2016-01-15
- Gene:
- PSPC1-AS2 NIH gene
- Name:
- PSPC1 antisense RNA 2
- Previous symbol:
- -
- Synonyms:
- RP11-523H24.3
- Chromosome:
- 13q12.11
- Locus Type:
- RNA, long non-coding
- Date approved:
- 2016-12-21
- Date modifiied:
- 2017-03-22
- Gene:
- RBM27 NIH gene
- Name:
- RNA binding motif protein 27
- Previous symbol:
- -
- Synonyms:
- KIAA1311, ARRS1, Psc1, ZC3H20
- Chromosome:
- 5q32
- Locus Type:
- gene with protein product
- Date approved:
- 2004-04-23
- Date modifiied:
- 2018-11-19
- Gene:
- SUMO2 NIH gene
- Name:
- small ubiquitin like modifier 2
- Previous symbol:
- SMT3H2
- Synonyms:
- SMT3B
- Chromosome:
- 17q25
- Locus Type:
- gene with protein product
- Date approved:
- 1997-01-29
- Date modifiied:
- 2019-02-18
- Gene:
- SUMO2P1 NIH gene
- Name:
- SUMO2 pseudogene 1
- Previous symbol:
- SMT3H2P, SUMO2P
- Synonyms:
- SMT3Bp, dJ271M21
- Chromosome:
- 6p22.1
- Locus Type:
- pseudogene
- Date approved:
- 2003-05-22
- Date modifiied:
- 2014-11-19
Related products to: CDH17 [3H2] Monoclonal Antibody
Related articles to: CDH17 [3H2] Monoclonal Antibody
- Dynein axonemal assembly factors (DNAAF) are essential for the assembly and transport of dynein motor complexes, which are crucial for the movement of cilia. Mutations in genes encoding these proteins often lead to motile ciliopathies called primary ciliary dyskinesia (PCD). In humans, loss-of-function mutations of Cilia and flagella-associated protein 300 (CFAP300, also known as DNAAF17) have been reported to cause PCD. The function of CFAP300 during embryogenesis, however, has not been reported. We carried out functional studies using zebrafish to understand its function during vertebrate development. - Source: PubMed
Publication date: 2026/05/01
Nayak UsharaniSahoo KalyaniBarrodia PraveenSwain Rajeeb K - BI 905711, a TRAILR2/cadherin-17 (CDH17) bispecific antibody, demonstrated preclinical apoptotic pathway activation and antitumor activity. Two phase Ia/Ib studies tested BI 905711 monotherapy (NCT04137289) or combination therapy (NCT05087992) in advanced, refractory gastrointestinal (GI) cancers. - Source: PubMed
Harding James JHofheinz RalfÉlez ElenaKuboki YasutoshiRasco Drew WCecchini MichaelShen LinHe MinArchuadze ShorenaChhaya NirajHaderk FranziskaMészáros LisaWölke StefanKatakabe TetsuyaLorence Robert MVan Cutsem EricKopetz ScottPant Shubham - Cadherin-17 (CDH17, LI-cadherin) is a non-classical cadherin with restricted expression in normal gastrointestinal epithelium, emerging as a multifunctional molecule in cancer. CDH17 regulates cell–cell adhesion, modulates key signaling pathways, and interacts with the tumor microenvironment, collectively influencing proliferation, invasion, metastasis, therapeutic resistance, and immune evasion. Its expression is highly context-dependent and dynamically regulated, with both upregulation and loss linked to distinct features of tumor aggressiveness and differentiation. CDH17 also interfaces with pathways governing stemness and cellular plasticity, suggesting a role in modulating therapeutic response and resistance mechanisms. Beyond its biological functions, CDH17 has been investigated as a diagnostic marker, with tissue-based detection, circulating biomarkers, and radiolabeled imaging probes exploiting its tumor-restricted expression and membrane localization, offering opportunities for noninvasive tumor detection, staging, and monitoring. CDH17 also holds potential prognostic significance, although its clinical relevance varies according to molecular context and tumor differentiation status, emphasizing the need for integrative biomarker assessment. Finally, the tumor-specific expression of CDH17 has inspired multiple therapeutic strategies, including cellular immunotherapies, antibody–drug conjugates, immunotoxins, radiolabeled agents, and engineered delivery platforms, all designed to selectively target CDH17-expressing cells while minimizing off-target toxicity. Such strategies highlight the translational potential of CDH17 as both a therapeutic target and a platform for precision oncology. In this review, we summarize the molecular mechanisms, biological functions, diagnostic and prognostic relevance, and therapeutic applications of CDH17. By integrating current findings and addressing existing challenges, we aim to provide a comprehensive overview of its multifaceted roles and to emphasize emerging strategies to harness this molecule for clinical applications in cancer. - Source: PubMed
Publication date: 2026/04/02
Fernandez BenjaminLopez LéaMatis ThibautDabernat SandrineAmintas Samuel - Chemoresistance greatly impairs the effectiveness of chemotherapy in gastric cancer (GC) patients. According to our prior results, Cadherin-17 (CDH17) contributes to chemoresistance in GC through activating the Wnt/β-catenin pathway; however, its specific molecular mechanisms require further elucidation. We compared the Wnt/β-catenin pathway activation levels between cisplatin (DDP)-resistant GC cell lines and their parental cell lines. Subsequently, we carried out loss-of-function and gain-of-function tests to investigate CDH17 for its effect on regulating β-catenin expression, nuclear transport, as well as transcriptional activity within DDP-resistant GC cells. Additionally, CDH17 was examined for its role in the expression of four ABC transporters using molecular assays. Finally, rescue experiments were carried out using the Wnt signaling pathway agonist CP21R7 and inhibitor IWR-1 to elucidate the specific mechanism of CDH17 in promoting chemotherapy resistance of GC cells. The results showed that the activation level of the Wnt/β-catenin signaling pathway was significantly elevated in DDP-resistant GC cell lines compared to their parental cell lines. Silencing CDH17 resulted in reduced expression, impaired nuclear translocation, and decreased transcriptional activity of β-catenin, whereas overexpression of CDH17 had the opposite effects. Notably, CDH17 was shown to specifically regulate the expression of ABCB1 (protein name: P-glycoprotein, P-gp) in resistant cells, with no observable impact on the other three ABC transporters (ABCC1, ABCG2, and ABCC2) examined. Importantly, treatment with IWR-1 effectively reversed the enhancing effect of CDH17 overexpression on P-gp protein expression, as well as its suppressive effects on DDP accumulation and chemosensitivity. Conversely, administration of CP21R7 attenuated the inhibitory consequences of CDH17 silencing on P-gp expression, DDP efflux, and drug resistance. In conclusion, CDH17 promotes the expression and nuclear translocation of β-catenin in GC cells, leading to activation of the Wnt/β-catenin signaling pathway, which subsequently upregulates ABCB1/P-gp expression and enhances cellular capacity for DDP efflux. These findings imply that targeting CDH17 could be a potential strategy for overcoming chemotherapy resistance in GC. - Source: PubMed
Publication date: 2026/03/23
Liu MengHan ZhengZhong ZiqiangTan JieZhu QingxiChen WeiHuang ShashaChen XiaoliTian Xia - Barrett's esophagus (BE) represents a critical precancerous lesion arising from chronic gastroesophageal reflux disease (GERD), with significant risk of progression to esophageal adenocarcinoma. Despite advances in transcriptomic technologies, including single-cell RNA sequencing (scRNA-seq), the molecular mechanisms underlying the GERD-to-BE transition remain incompletely understood. Comprehensive transcriptomic profiling at both bulk and, prospectively, single-cell resolution is essential for identifying disease-driving molecular signatures and cellular heterogeneity. This study aimed to systematically characterize the transcriptomic landscape of GERD and Barrett's esophagus through integrative bulk RNA-sequencing analysis, with the goal of establishing a foundational framework for future single-cell transcriptomic investigations. - Source: PubMed
Publication date: 2026/03/14
Jiang ShanshanWang XiuminChen YujunDong WeihuaXu JingZhang ChunlanZhou ChunYu Chun